6.15
+0.23(+3.89%)
Currency In USD
| Previous Close | 5.92 |
| Open | 5.9 |
| Day High | 6.16 |
| Day Low | 5.77 |
| 52-Week High | 7.37 |
| 52-Week Low | 2.41 |
| Volume | 1.16M |
| Average Volume | 1.2M |
| Market Cap | 478.89M |
| PE | -2.2 |
| EPS | -2.79 |
| Moving Average 50 Days | 5.98 |
| Moving Average 200 Days | 4.55 |
| Change | 0.23 |
If you invested $1000 in Solid Biosciences Inc. (SLDB) since IPO date, it would be worth $18.13 as of September 29, 2025 at a share price of $6.15. Whereas If you bought $1000 worth of Solid Biosciences Inc. (SLDB) shares 5 years ago, it would be worth $199.03 as of September 29, 2025 at a share price of $6.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHEN
Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
GlobeNewswire Inc.
Sep 23, 2025 12:00 PM GMT
- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible fo
Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
- SGT-501 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations - - Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatenin